Details der Publikation - Tranilast in COVID19

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 12. Juli Zur Gesamtaufnahme - year:2021

Sprache:	Unbestimmt

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: COVID19. COVID-19, virus identified;U07.1 Phase: Phase 2/Phase 3 Recruitment Status: Completed Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-04-22, Last updated: 2022-11-24

ICTRP ID:	IRCT20200419047128N1

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG005084520


LEADER	01000caa a22002652 4500
001	CTG005084520
003	DE-627
005	20230425170415.0
007	cr uuu---uuuuu
008	210507s2021 xx \|\|\|\|\|o 00\| \|\|und c
035			\|a (DE-627)CTG005084520
035			\|a (UBBS_Klinische_Studien_WHO)IRCT20200419047128N1
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a und
245	1	0	\|a Tranilast in COVID19 \|b Assessment of the effect of Tranilast (novel NLRP3 Inflammasome inhibitor ) on the efficacy of antiviral drug regimens in the treatment of patients with severe COVID19
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2020-04-22, Last updated: 2022-11-24
650		4	\|a Medical Condition: COVID19. COVID-19, virus identified;U07.1
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2/Phase 3
650		4	\|a Recruitment Status: Completed
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 12. Juli
773	1	8	\|g year:2021 \|g day:12 \|g month:07
856	4	0	\|u http://en.irct.ir/trial/47265 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 12 \|c 07